GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
26 Apr 2023
VaccinePhase 2Immunotherapy
ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on Infectious Diseases in the Immunocompromised Host, being held April 30 to May 2, 2023, in Seattle, Washington and hosted by the Fred Hutchinson Cancer Center. Medical leadership representation from GeoVax will attend the event and will meet and interact with the symposium speakers and attendees.
The 4th Symposium on Infectious Diseases in the Immunocompromised Host brings together leaders and trainees in research and clinical care of infectious diseases in the immunocompromised host. The program features outstanding, internationally recognized experts in the field, representing more than 20 institutions, who will speak on topics including infections in solid organ transplant, hematopoietic cell transplant, and oncology. The symposium will address COVID-19, fungal disease, respiratory viruses, CMV, HHV-6, immunotherapy, the microbiome, and antimicrobial stewardship.
David Dodd, GeoVax’s Chairman and CEO, commented, “We are proud to participate in this important symposium which highlights the critical need for innovative approaches to preventing and treating infections in vulnerable populations. At GeoVax, we remain committed to advancing novel vaccine technologies such as CM04S1, our next-generation COVID-19 vaccineCOVID-19 vaccine being studied in two Phase 2 trials, that can potentially help protect and improve the lives of immunocompromised individuals, representing those who are most susceptible to infectious diseases.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccineCOVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a COVID-19 vaccineCOVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccinesCOVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.
For additional information about GeoVax, visit our website: .
Investor Relations Contact:
Rich Cockrell
CG Capital
404-736-3838
govx@cg.capital
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.